Loading
A phase 1/2 trial of APG-115 in neuroblastoma, run by Ascentage Pharma Group Inc., now recruiting.
APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors is a phase 1/2 interventional study registered as NCT05701306 by Ascentage Pharma Group Inc., with 100 participants planned, started 2023-02-28 and due to reach its primary completion in 2027-06-01. Interventions recorded: APG-115 and APG-2575.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ascentage Pharma and the tag pipeline.
Shares Ascentage Pharma and the tag pipeline.
Shares Neuroblastoma (paediatric) and the tag pipeline.
Shares Ascentage Pharma and the tag pipeline.
Shares Ascentage Pharma and the tag pipeline.
Shares Ascentage Pharma and the tag pipeline.
Shares Neuroblastoma (paediatric) and the tag pipeline.
Shares Neuroblastoma (paediatric) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/